|
SETX expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62458935193399E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.55111512312578E-16 |
| Normal-vs-Stage2 |
2.09930000050207E-07 |
| Normal-vs-Stage3 |
5.55111512312578E-16 |
| Normal-vs-Stage4 |
6.66133814775094E-16 |
| Stage1-vs-Stage2 |
4.456200E-01 |
| Stage1-vs-Stage3 |
8.369700E-02 |
| Stage1-vs-Stage4 |
4.026900E-04 |
| Stage2-vs-Stage3 |
6.323700E-02 |
| Stage2-vs-Stage4 |
3.462100E-03 |
| Stage3-vs-Stage4 |
8.907600E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
4.71369999999194E-06 |
| Normal-vs-Asian |
2.21267448807794E-13 |
| Caucasian-vs-AfricanAmerican |
4.277000E-01 |
| Caucasian-vs-Asian |
1.634000E-01 |
| AfricanAmerican-vs-Asian |
1.053610E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.22044604925031E-16 |
| Normal-vs-Female |
1.6242562850266E-12 |
| Male-vs-Female |
4.310800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.66822111680176E-12 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
1.63014046705712E-12 |
| Normal-vs-Age(81-100Yrs) |
2.027500E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.117000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.416410E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.149400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.309400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.186600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.846600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.98529999999786E-05 |
| Classical-VS-Follicular |
3.168800E-01 |
| Classical-VS-Other |
2.240200E-01 |
| Classical-VS-Normal |
1.56820112451328E-11 |
| Tall-VS-Follicular |
6.32990000000166E-05 |
| Tall-VS-Other |
6.090200E-01 |
| Tall-VS-Normal |
1.6251444634463E-12 |
| Follicular-VS-Other |
1.969000E-01 |
| Follicular-VS-Normal |
1.01589999745855E-08 |
| Other-VS-Normal |
1.182230E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.55351295663786E-15 |
| Normal-vs-N1 |
1.82076576038526E-14 |
| N0-vs-N1 |
1.477700E-02 |
|
|
